Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 08, 2022 07:00 ET | Source: Altimmune, Inc

Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022

GAITHERSBURG, Md., March 08, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year...
January 31, 2022 07:00 ET | Source: Altimmune, Inc

Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity

GAITHERSBURG, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...
January 03, 2022 07:00 ET | Source: Altimmune, Inc

Altimmune to Present Pemvidutide Clinical Data at Upcoming NASH-TAG Conference January 8, 2022

GAITHERSBURG, Md., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at...
December 13, 2021 06:00 ET | Source: Altimmune, Inc

Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GAITHERSBURG, Md., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Compensation Committee of its Board of...
December 13, 2021 06:00 ET | Source: Altimmune, Inc

Altimmune Appoints Richard Eisenstadt as Chief Financial Officer

GAITHERSBURG, Md., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases, today...
November 22, 2021 16:01 ET | Source: Altimmune, Inc

Altimmune to Present at Upcoming Investor and Scientific Conferences

GAITHERSBURG, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be...
November 10, 2021 16:01 ET | Source: Altimmune, Inc

Altimmune to Present at Upcoming Investor Conferences

GAITHERSBURG, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be...
November 09, 2021 16:01 ET | Source: Altimmune, Inc

Altimmune Announces Third Quarter 2021 Financial Results and Provides a Corporate Update

Exploratory MRI-PDFF analysis of subjects with hepatic steatosis in recently completed Phase 1 study of pemvidutide shows reduction of liver fat to undetectable levels after 6 weeks of treatment ...
November 03, 2021 16:01 ET | Source: Altimmune, Inc

Altimmune to Announce Third Quarter 2021 Financial Results on November 10, 2021

GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2021 financial...
October 06, 2021 16:01 ET | Source: Altimmune, Inc

Altimmune to Present at Upcoming H.C. Wainwright Investor Conferences October 12-13, 2021

GAITHERSBURG, Md., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will be presenting...